Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CEA CAR T cell therapy - Sorrento Therapeutics

Next Previous
X
Search
Drug Profile

Anti CEA CAR T cell therapy - Sorrento Therapeutics

Alternative Names: Anti-CEA CAR-T; Anti-CEA T-cells; CAR-T CEA; CAR-T-CEA-therapy; CAR2Anti-CEA CAR-T Cells; CEA CART; Designer T-cells; Gene modified patient T cells - Sorrento Therapeutics

Latest Information Update: 28 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC
  • Developer Sorrento Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Liver metastases; Malignant ascites; Pancreatic cancer

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer(Metastatic disease, Second-line therapy or greater) in USA (Intrahepatic, Infusion)
  • 28 Feb 2022 Sorrento Therapeutics terminates a phase I trial in Pancreatic cancer (Metastatic disease, Second-line therapy or greater) in USA due to slow patients accrual (Intrahepatic) (NCT03818165)
  • 31 Mar 2021 No development reported - Phase-II for Liver metastases (Inoperable/Unresectable, Second-line therapy or greater) in USA (Intrahepatic)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top